{"id":"NCT00663260","sponsor":"AstraZeneca","briefTitle":"Glycemic Efficacy and Renal Safety Study of Dapagliflozin in Subjects With Type 2 Diabetes Mellitus and Moderate Renal Impairment","officialTitle":"A Multicenter, Double-Blind, Placebo-Controlled, Parallel Group, Randomized, Phase 2/3 Trial to Evaluate the Glycemic Efficacy, Renal Safety, Pharmacokinetics, and Pharmacodynamics of Dapagliflozin in Subjects With Type 2 Diabetes Mellitus and Moderate Renal Impairment Who Have Inadequate Glycemic Control","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2008-06","primaryCompletion":"2009-12","completion":"2011-06","firstPosted":"2008-04-22","resultsPosted":"2017-02-10","lastUpdate":"2017-02-10"},"enrollment":631,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Diabetes Mellitus, Type 2"],"interventions":[{"type":"DRUG","name":"Dapagliflozin","otherNames":["BMS-512148"]},{"type":"DRUG","name":"Dapagliflozin","otherNames":["BMS-512148"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Dapagliflozin (10 mg)","type":"ACTIVE_COMPARATOR"},{"label":"Dapagliflozin (5 mg)","type":"ACTIVE_COMPARATOR"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to determine whether dapagliflozin is effective in the treatment of type 2 diabetes in subjects with poor blood sugar control and moderate renal impairment","primaryOutcome":{"measure":"Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 24 (Last Observation Carried Forward [LOCF]","timeFrame":"From Baseline to Week 24","effectByArm":[{"arm":"Placebo","deltaMin":-0.32,"sd":0.1701},{"arm":"Dapagliflozin 5 mg","deltaMin":-0.41,"sd":0.1701},{"arm":"Dapagliflozin 10 mg","deltaMin":-0.44,"sd":0.1708}],"pValues":[{"comp":"OG000 vs OG001","p":"0.561"},{"comp":"OG000 vs OG002","p":"0.435"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":4},"locations":{"siteCount":96,"countries":["United States","Argentina","Australia","Canada","Denmark","France","India","Italy","Mexico","Peru","Puerto Rico","Singapore","Spain"]},"refs":{"pmids":["38770818","27306615","24067431"],"seeAlso":["http://rd.springer.com/article/10.1007%2Fs00125-016-4017-1","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3973038/","http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=3639&filename=MB102029_Redacted_CSR_synopsis.pdf"]},"adverseEventsSummary":{"seriousAny":{"events":9,"n":84},"commonTop":["HYPERKALAEMIA","DIZZINESS","POLLAKIURIA","COUGH","OEDEMA PERIPHERAL"]}}